Patent · US Active

Use of chemically modified heparin derivates in sickle cell disease

US9480702B2 · kind B2 · utility

0Cited by

13References

12Claims

0Family size

Assignee

DILAFORETTE AB · SE

Inventors

Hans-Peter Ekre · Stockholm, SE
Anna Leitgeb · Hallsberg, SE
Mats Wahlgren · Stocksund, SE
Dagmar Pikas · Upplands Väsby, SE

Key dates

Filing date	Dec 19, 2012
Grant date	Nov 1, 2016
Priority date	—
Expiry date	Dec 19, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.